UI Hospitals and Clinics
Study for Patients with Rhabdomyosarcoma (RMS)
ARST0921: A randomized phase II trial of bevacizumab (IND 7921, Avastin) and temsirolimus (IND61010, torisel) in combination with intravenous vinorelbine and cyclophosphamide in patients with recurrent/refractory rhabdomyosarcoma
Participants in this study have Rhabdomyosarcoma (RMS). Rhabdomyosarcoma occurs in soft tissues like the muscles and it can occur in many places in the body. This cancer is recurrent or refractory. Recurrent means that the cancer has come back after treatment. Refractory means that the cancer has not responded to treatment. The purpose of this study is to test 2 experimental drug combinations in the hope of finding a new therapy for fighting this particular cancer. The 2 drug combinations are: 1) vinorelbine and cyclophosphamide with bevacizumab 2) vinorelbine and cyclophosphamide with temsirolimus
Approximately 4 people will take part in this study conducted by investigators at the University of Iowa. The total number of people enrolled on this study nationwide is expected to be 100
Victoria Scaccia, 319-356-7875
We welcome your feedback! Please help us improve your experience on our website by completing a brief survey.